Agents that stabilize mutated von Hippel-Lindau (VHL) protein: Results of a high-throughput screen to identify compounds that modulate VHL proteostasis

Journal of Biomolecular Screening

Volumn 17, Issue 5, 2012, Pages 572-580

  Ding, Zhiyong ^a   German, Peter ^a   Bai, Shanshan ^a   Feng, Zhehui ^a   Gao, Meng ^a   Si, Wendy ^a   Sobieski, Mary M ^a   Stephan, Clifford C ^a   Mills, Gordon B ^a   Jonasch, Eric ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

high throughput screen; Prestwick; proteostasis; VHL upregulation

Indexed keywords

8 AZAGUANINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; FLUORESCENT DYE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROTEASOME INHIBITOR; THIOGUANOSINE; THIOSTREPTON; UNCLASSIFIED DRUG; VENUS FLUORESCENT PROTEIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CELL LEVEL; CELL LINE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PHARMACOPHORE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STABILITY; UPREGULATION; VON HIPPEL LINDAU DISEASE; WESTERN BLOTTING;

CELL LINE; CYSTEINE PROTEINASE INHIBITORS; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LEUPEPTINS; MUTANT PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84861818456     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057112436557     Document Type: Article

References (29)

1. Molino D., Sepe J., Anastasio P., De Santo N. G.. The History of von Hippel-Lindau Disease. J. Nephrol. 2006 ; 19 (Suppl 10). S119 - S123
2. Latif F., Tory K., Gnarra J., Yao M., Duh F. M., Orcutt M. L., Stackhouse T., Kuzmin I., Modi W., Geil L., et al. Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene. Science. 1993 ; 260 (5112). 1317-1320
3. Kibel A., Iliopoulos O., DeCaprio J. A., Kaelin W. G.. Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C. Science. 1995 ; 269 (5229). 1444-1446
4. Lonergan K. M., Iliopoulos O., Ohh M., Kamura T., Conaway R. C., Conaway J. W., Kaelin W. G.. Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2. Mol. Cell. Biol. 1998 ; 18 (2). 732-741
5. Maxwell P. H., Wiesener P. H., Wiesener M. S., Chang G. W., Clifford S. C., Vaux E. C., Cockman M. E., Wykoff C. C., Pugh C. W., Maher E. R., Ratcliffe P. J.. The Tumour Suppressor Protein VHL Targets Hypoxia-Inducible Factors for Oxygen-Dependent Proteolysis. Nature. 1999 ; 399 (6733). 271-275
6. Jaakkola P., Mole D. R., Tian Y. M., Wilson M. I., Gielbert J., Gaskell S. J., Kriegsheim A., Hebestreit H. F., Mukherji M., Schofield C. J., et al. Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation. Science. 2001 ; 292 (5516). 468-472
7. Escudier B., Eisen T., Stadler W. M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A. A., et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N. Engl. J. Med. 2007 ; 356 (2). 125-134
8. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., Chevreau C., Filipek M., Melichar B., Bajetta E., et al. Bevacizumab plus Interferon alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial. Lancet. 2007 ; 370 (9605). 2103-2111
9. Motzer R. J., Hutson T. E., Tomczak P., Michaelson M. D., Bukowski R. M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S. T., et al. Sunitinib versus Interferon alfa in Metastatic Renal-Cell Carcinoma. N. Engl. J. Med. 2007 ; 356 (2). 115-124
10. Sternberg C. N., Davis I. D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C. H., Salman P., Gladkov O. A., Kavina A., et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J. Clin. Oncol. 2010 ; 28 (6). 1061-1068
11. Esteban M. A., Harten S. K., Tran M. G., Maxwell P. H.. Formation of Primary Cilia in the Renal Epithelium Is Regulated by the von Hippel-Lindau Tumor Suppressor Protein. J. Am. Soc. Nephrol. 2006 ; 17 (7). 1801-1806
12. Kurban G., Hudon V., Duplan E., Ohh M., Pause A.. Characterization of a von Hippel Lindau Pathway Involved in Extracellular Matrix Remodeling, Cell Invasion, and Angiogenesis. Cancer Res. 2006 ; 66 (3). 1313-1319
13. Ohh M., Yauch R. L., Lonergan K. M., Whaley J. M., Stemmer-Rachamimov A. O., Louis D. N., Gavin B. J., Kley N., Kaelin W. G., Iliopoulos O.. The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix. Mol Cell. 1998 ; 1 (7). 959-968
14. Richards F. M., Crossey P. A., Phipps M. E., Foster K., Latif F., Evans G., Sampson J., Lerman M. I., Zbar B., Affara N. A., et al. Detailed Mapping of Germline Deletions of the von Hippel-Lindau Disease Tumour Suppressor Gene. Hum. Mol. Genet. 1994 ; 3 (4). 595-598
15. Zbar B., Kishida T., Chen F., Schmidt L., Maher E. R., Richards F. M., Crossey P. A., Webster A. R., Affara N. A., Ferguson-Smith M. A., et al. Germline Mutations in the von Hippel-Lindau Disease (VHL) Gene in Families from North America, Europe, and Japan. Hum. Mutat. 1996 ; 8 (4). 348-357
16. Schoenfeld A., Davidowitz E. J., Burk R. D.. A Second Major Native von Hippel-Lindau Gene Product, Initiated from an Internal Translation Start Site, Functions as a Tumor Suppressor. Proc. Natl. Acad. Sci. U. S. A. 1998 ; 95 (15). 8817-8822
17. Nordstrom-O'Brien M., van der Luijt R. B., van Rooijen E., van den Ouweland A. M., Majoor-Krakauer D. F., Lolkema M. P., van Brussel A., Voest E. E., Giles R. H.. Genetic Analysis of von Hippel-Lindau Disease. Hum. Mutat. 2010 ; 31 (5). 521-537
18. Schoenfeld A. R., Davidowitz E. J., Burk R. D.. Elongin BC Complex Prevents Degradation of von Hippel-Lindau Tumor Suppressor Gene Products. Proc. Natl. Acad. Sci. U. S. A. 2000 ; 97 (15). 8507-8512
19. Feldman D. E., Spiess C., Howard D. E., Frydman J.. Tumorigenic Mutations in VHL Disrupt Folding In Vivo by Interfering with Chaperonin Binding. Mol. Cell. 2003 ; 12 (5). 1213-1224
20. McClellan A. J., Scott M. D., Frydman J.. Folding and Quality Control of the VHL Tumor Suppressor Proceed through Distinct Chaperone Pathways. Cell. 2005 ; 121 (5). 739-748
21. Feldman D. E., Thulasiraman V., Ferreyra R. G., Frydman J.. Formation of the VHL-Elongin BC Tumor Suppressor Complex Is Mediated by the Chaperonin TRiC. Mol Cell. 1999 ; 4 (6). 1051-1061
22. Schoenfeld A. R., Parris T., Eisenberger A., Davidowitz E. J., De Leon M., Talasazan F., Devarajan P., Burk R. D.. The von Hippel-Lindau Tumor Suppressor Gene Protects Cells from UV-Mediated Apoptosis. Oncogene. 2000 ; 19 (51). 5851-5857
23. Nagai T., Ibata K., Park E. S., Kubota M., Mikoshiba K., Miyawaki A.. A Variant of Yellow Fluorescent Protein with Fast and Efficient Maturation for Cell-Biological Applications. Nat. Biotechnol. 2002 ; 20 (1). 87-90
24. Ding Z., Liang J., Lu Y., Yu Q., Songyang Z., Lin S. Y., Mills G. B.. A Retrovirus-Based Protein Complementation Assay Screen Reveals Functional AKT1-Binding Partners. Proc. Natl. Acad. Sci. U. S. A. 2006 ; 103 (41). 15014-15019
25. Szafran A. T., Szwarc M., Marcelli M., Mancini M. A.. Androgen Receptor Functional Analyses by High Throughput Imaging: Determination of Ligand, Cell Cycle, and Mutation-Specific Effects. PLoS One. 2008 ; 3 (11). e3605
26. Yuen J. S., Cockman M. E., Sullivan M., Protheroe A., Turner G. D., Roberts I. S., Pugh C. W., Werner H., Macaulay V. M.. The VHL Tumor Suppressor Inhibits Expression of the IGF1R and Its Loss Induces IGF1R Upregulation in Human Clear Cell Renal Carcinoma. Oncogene. 2007 ; 26 (45). 6499-6508
27. Xia M., Bi K., Huang R., Cho M. H., Sakamuru S., Miller S. C., Li H., Sun Y., Printen J., Austin C. P., Inglese J.. Identification of Small Molecule Compounds That Inhibit the HIF-1 Signaling Pathway. Mol Cancer. 2009 ; 8: 117
28. Pandit B., Gartel A. L.. Thiazole Antibiotic Thiostrepton Synergize with Bortezomib to Induce Apoptosis in Cancer Cells. PLoS One. 2011 ; 6 (2). e17110
29. Roe J. S., Kim H., Lee S. M., Kim S. T., Cho E. J., Youn H. D.. 53 Stabilization and Transactivation by a von Hippel-Lindau Protein. Mol Cell. 2006 ; 22 (3). 395-405